Cargando…

Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies

The elicitation of broadly neutralizing antibodies (bNAbs) is likely to be essential for a preventative HIV-1 vaccine, but this has not yet been achieved by immunization. In contrast some HIV-1-infected individuals naturally mount bNAb responses during chronic infection, suggesting that years of mat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bhiman, Jinal N., Anthony, Colin, Doria-Rose, Nicole A., Karimanzira, Owen, Schramm, Chaim A., Khoza, Thandeka, Kitchin, Dale, Botha, Gordon, Gorman, Jason, Garrett, Nigel J., Abdool Karim, Salim S., Shapiro, Lawrence, Williamson, Carolyn, Kwong, Peter D., Mascola, John R., Morris, Lynn, Moore, Penny L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4637988/ https://www.ncbi.nlm.nih.gov/pubmed/26457756 http://dx.doi.org/10.1038/nm.3963

Ejemplares similares

A1 The role of virus-antibody co-evolution in the development of a V3-glycan-directed HIV-1 broadly neutralizing antibody lineage
por: Kitchin, D, et al.
Publicado: (2019)

Sequencing HIV-neutralizing antibody exons and introns reveals detailed aspects of lineage maturation
por: Johnson, Erik L., et al.
Publicado: (2018)

Somatic hypermutation to counter a globally rare viral immunotype drove off-track antibodies in the CAP256-VRC26 HIV-1 V2-directed bNAb lineage
por: Sacks, David, et al.
Publicado: (2019)

Effects of Darwinian Selection and Mutability on Rate of Broadly Neutralizing Antibody Evolution during HIV-1 Infection
por: Sheng, Zizhang, et al.
Publicado: (2016)

Viral Escape from HIV-1 Neutralizing Antibodies Drives Increased Plasma Neutralization Breadth through Sequential Recognition of Multiple Epitopes and Immunotypes
por: Wibmer, Constantinos Kurt, et al.
Publicado: (2013)

A38 Diversity analyses of HIV-1 envelope glycoproteins in HIV-infected individuals with and without broadly neutralizing antibodies
por: Mabvakure, B., et al.
Publicado: (2017)

Leveraging South African HIV research to define SARS‐CoV‐2 immunity triggered by sequential variants of concern
por: Bhiman, Jinal N., et al.
Publicado: (2022)

Broadly Neutralizing Antibodies as Treatment: Effects on Virus and Immune System
por: Bhiman, Jinal N., et al.
Publicado: (2017)

V2-Directed Vaccine-like Antibodies from HIV-1 Infection Identify an Additional K169-Binding Light Chain Motif with Broad ADCC Activity
por: van Eeden, Charmaine, et al.
Publicado: (2018)

Ontogeny‐based immunogens for the induction of V2‐directed HIV broadly neutralizing antibodies
por: Moore, Penny L., et al.
Publicado: (2017)

HIV Superinfection Drives De Novo Antibody Responses and Not Neutralization Breadth
por: Sheward, Daniel J., et al.
Publicado: (2018)

Positive Selection at Key Residues in the HIV Envelope Distinguishes Broad and Strain-Specific Plasma Neutralizing Antibodies
por: Mabvakure, Batsirai M., et al.
Publicado: (2019)

Structure of an N276-Dependent HIV-1 Neutralizing Antibody Targeting a Rare V5 Glycan Hole Adjacent to the CD4 Binding Site
por: Wibmer, Constantinos Kurt, et al.
Publicado: (2016)

HIV Coinfection Provides Insights for the Design of Vaccine Cocktails to Elicit Broadly Neutralizing Antibodies
por: Sheward, Daniel J., et al.
Publicado: (2022)

Structures of HIV-1-Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design
por: Gorman, Jason, et al.
Publicado: (2015)

Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape
por: Wibmer, Constantinos Kurt, et al.
Publicado: (2017)

Cooperation between Strain-Specific and Broadly Neutralizing Responses Limited Viral Escape and Prolonged the Exposure of the Broadly Neutralizing Epitope
por: Anthony, Colin, et al.
Publicado: (2017)

Dependence on a variable residue limits the breadth of an HIV MPER neutralizing antibody, despite convergent evolution with broadly neutralizing antibodies
por: Scheepers, Cathrine, et al.
Publicado: (2022)

SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies
por: Moyo-Gwete, Thandeka, et al.
Publicado: (2021)

Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351)
por: Moyo-Gwete, Thandeka, et al.
Publicado: (2021)

Clinical Trials of Broadly Neutralizing Monoclonal Antibodies for Human Immunodeficiency Virus Prevention: A Review
por: Mahomed, Sharana, et al.
Publicado: (2020)

IgG3 enhances neutralization potency and Fc effector function of an HIV V2-specific broadly neutralizing antibody
por: Richardson, Simone I., et al.
Publicado: (2019)

A short segment in the HIV-1 gp120 V1/V2 region is a major determinant of neutralization resistance to PG9-like antibodies
por: Doria-Rose, NA, et al.
Publicado: (2012)

SONAR: A High-Throughput Pipeline for Inferring Antibody Ontogenies from Longitudinal Sequencing of B Cell Transcripts
por: Schramm, Chaim A., et al.
Publicado: (2016)

Identification of broadly neutralizing antibody epitopes in the HIV-1 envelope glycoprotein using evolutionary models
por: Lacerda, Miguel, et al.
Publicado: (2013)

Trapping the HIV-1 V3 loop in a helical conformation enables broad neutralization
por: Glögl, Matthias, et al.
Publicado: (2023)

Antibody Isotype Switching as a Mechanism to Counter HIV Neutralization Escape
por: Scheepers, Cathrine, et al.
Publicado: (2020)

Gene-Specific Substitution Profiles Describe the Types and Frequencies of Amino Acid Changes during Antibody Somatic Hypermutation
por: Sheng, Zizhang, et al.
Publicado: (2017)

South African HIV-1 subtype C transmitted variants with a specific V2 motif show higher dependence on α4β7 for replication
por: Richardson, Simone I, et al.
Publicado: (2015)

Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection
por: Wagh, Kshitij, et al.
Publicado: (2016)

Antibodyomics: bioinformatics technologies for understanding B‐cell immunity to HIV‐1
por: Kwong, Peter D., et al.
Publicado: (2017)

HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodies
por: Richardson, Simone I., et al.
Publicado: (2018)

Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trial
por: Mahomed, Sharana, et al.
Publicado: (2020)

Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic
por: Karim, Salim S Abdool, et al.
Publicado: (2021)

AAV-Mediated Expression of Broadly Neutralizing and Vaccine-like Antibodies Targeting the HIV-1 Envelope V2 Region
por: van den Berg, Fiona T., et al.
Publicado: (2019)

Design of an HIV Env antigen that binds with high affinity to antibodies against linear, conformational and broadly neutralizing epitopes within V1/V2
por: Liao, L, et al.
Publicado: (2012)

Vaccines and SARS-CoV-2 variants: the urgent need for a correlate of protection
por: Karim, Salim S Abdool
Publicado: (2021)

Broad coverage of neutralization-resistant SIV strains by second-generation SIV-specific antibodies targeting the region involved in binding CD4
por: Welles, Hugh C., et al.
Publicado: (2022)

Isolation of broadly neutralizing HIV-1 antibodies from high-throughput single B cell culture
por: Longo, NS, et al.
Publicado: (2012)

SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection
por: Cele, Sandile, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qtbl41d2vst7mqs92q5kfokvgc